计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T413986-5mg |
5mg |
现货 ![]() |
| |
| T413986-25mg |
25mg |
现货 ![]() |
| |
| T413986-50mg |
50mg |
现货 ![]() |
| |
| T413986-100mg |
100mg |
现货 ![]() |
|
| 别名 | 图卡替尼(厄比尼替尼,ONT-380) |
|---|---|
| 英文别名 | Irbinitinib | ONT-380 | Q25100690 | 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine | UNII-234248D0HH | BDBM471617 | D11141 | Example 11 (WO2007059257A2) | N6-(4,5-Dihydro-4,4-dim |
| 规格或纯度 | Moligand™, ≥96% |
| 英文名称 | Tucatinib (Irbinitinib, ONT-380) |
| 生化机理 | 图卡替尼(Irbinitinib,ONT-380,ARRY-380)是一种口服、强效、选择性、可逆和 ATP 竞争性的 ErbB-2(又称 HER2)小分子抑制剂,在基于细胞的检测中,对 ErbB-2 和 p95 HER2 的 IC50 分别为 8 nM 和 7 nM,对 HER2 与表皮生长因子受体的选择性约为 500 倍。它具有潜在的抗肿瘤活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 受体蛋白-酪氨酸激酶 erbB-2 抑制剂 |
| 产品介绍 |
Tucatinib (Irbinitinib, ONT-380, ARRY-380) 是一种具有口服活性、可逆的、ATP竞争性的的ErbB2(HER2)小分子抑制剂。在细胞实验中,ARRY-380对ErbB-2和p95 HER2的IC50s分别为8 nM和7 nM,对HER2的选择性是对EGFR的500倍。具有潜在的抗肿瘤活性。 Information Tucatinib (Irbinitinib, ONT-380, ARRY-380) is an oral, potent, selective, reversible and ATP-competitive small-molecule inhibitor ofErbB-2(also called HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively in cell-based assays, showing ~500-fold selective for HER2 vs EGFR. It has potential antineoplastic activity. Targets p95 HER2 (Cell-based assay); ErbB2 (Cell-based assay) 7 nM; 8 nM In vitro The compound is a reversible, ATP-competitive inhibitor with nanomolar potency against ErbB2 in both in vitro and in cell-based assays. Incell-based assays, ARRY-380 is ~500-fold selective for HER2 vs. EGFR and is equipotent against truncated p95-HER2. In vivo ARRY-380 significantly inhibits tumor growth in multiple HER2-dependent tumor xenograft models. It shows excellent activity in numerous mouse tumor models including breast (BT-474, MDA-MB-453), ovarian (SKOV-3) and gastric (N87) carcinoma models. In the BT-474 model, ARRY-380 demonstrated significant dose-related tumor growth inhibition (TGI; 50% at 50 mg/kg/d and 96% at 100 mg/kg/d) with numerous partial regressions (>50% reduction from baseline size). |
| 纯度 | ≥96% |
| IC50 | ErbB2, IC50: 8 nM |
|---|---|
| ALogP | 4.744 |
| HBD Count | 2 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771007 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine |
| INCHI | 1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31) |
| InChi Key | SDEAXTCZPQIFQM-UHFFFAOYSA-N |
| Smiles | CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5 |
| Isomeric SMILES | CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5 |
| PubChem CID | 51039094 |
| 分子量 | 480.52 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 96 mg/mL (199.78 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 96 |
| DMSO(mM) Max Solubility | 199.7835678 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 480.500 g/mol |
| XLogP3 | 4.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 480.202 Da |
| 单同位素质量Monoisotopic Mass | 480.202 Da |
| 拓扑极表面积Topological Polar Surface Area | 111.000 Ų |
| 重原子数Heavy Atom Count | 36 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 796.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. (2017) Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).. Clin Cancer Res, 23 (14): (3529-3536). [PMID:28053022] |
| 2. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S. (2020) Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.. Mol Cancer Ther, 19 (4): (976-987). [PMID:32241871] |